Hygeia Ventures is SFDR Article 8 compliant with ESG and impact diligence embedded directly into the Investment Committee process. We invest in companies that generate returns while measurably improving patient outcomes and the resilience of European health systems.
Our impact framework traces the causal chain from the capital and expertise we deploy through company-level outputs to patient-facing outcomes and ultimately to system-wide impact.
Aggregate number of patients directly impacted by portfolio-company products and services.
Peer-reviewed or validated outcome data reported by each portfolio company where relevant.
Direct and indirect employment generated across the portfolio annually.
Emissions avoided through digitalisation, telemedicine and optimised clinical workflows.
ESG due diligence is integrated into the Investment Committee process. Each prospective investment is assessed against Hygeia Ventures' ESG policy, SFDR alignment, and contribution to the targeted SDGs before approval.
Hygeia Ventures Fund I is classified under Article 8 of Regulation (EU) 2019/2088 (SFDR), meaning it promotes environmental and social characteristics while maintaining good governance practices across the portfolio. Our approach to sustainability risks, principal adverse impacts, and the promotion of environmental and social characteristics is detailed in our Pre-contractual Disclosures, available to professional investors on request through the data room.
Full SFDR Pre-contractual Disclosure, Periodic Report template and ESG Policy available under NDA.